These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
579 related articles for article (PubMed ID: 33675984)
1. Gene fusion neoantigens: Emerging targets for cancer immunotherapy. Wang Y; Shi T; Song X; Liu B; Wei J Cancer Lett; 2021 May; 506():45-54. PubMed ID: 33675984 [TBL] [Abstract][Full Text] [Related]
2. Sources of Cancer Neoantigens beyond Single-Nucleotide Variants. Capietto AH; Hoshyar R; Delamarre L Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077528 [TBL] [Abstract][Full Text] [Related]
3. Neoantigen vaccine: an emerging tumor immunotherapy. Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694 [TBL] [Abstract][Full Text] [Related]
4. FusionNeoAntigen: a resource of fusion gene-specific neoantigens. Kumar H; Luo R; Wen J; Yang C; Zhou X; Kim P Nucleic Acids Res; 2024 Jan; 52(D1):D1276-D1288. PubMed ID: 37870454 [TBL] [Abstract][Full Text] [Related]
5. Neoantigens: promising targets for cancer therapy. Xie N; Shen G; Gao W; Huang Z; Huang C; Fu L Signal Transduct Target Ther; 2023 Jan; 8(1):9. PubMed ID: 36604431 [TBL] [Abstract][Full Text] [Related]
6. Tumor neoantigens: from basic research to clinical applications. Jiang T; Shi T; Zhang H; Hu J; Song Y; Wei J; Ren S; Zhou C J Hematol Oncol; 2019 Sep; 12(1):93. PubMed ID: 31492199 [TBL] [Abstract][Full Text] [Related]
7. Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy. Okada M; Shimizu K; Fujii SI Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269735 [TBL] [Abstract][Full Text] [Related]
11. MHC class II restricted neoantigen: A promising target in tumor immunotherapy. Sun Z; Chen F; Meng F; Wei J; Liu B Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443 [TBL] [Abstract][Full Text] [Related]
12. New emerging targets in cancer immunotherapy: the role of neoantigens. De Mattos-Arruda L; Blanco-Heredia J; Aguilar-Gurrieri C; Carrillo J; Blanco J ESMO Open; 2020 Apr; 4(Suppl 3):e000684. PubMed ID: 32269031 [TBL] [Abstract][Full Text] [Related]
13. Computational Prediction and Validation of Tumor-Associated Neoantigens. Roudko V; Greenbaum B; Bhardwaj N Front Immunol; 2020; 11():27. PubMed ID: 32117226 [TBL] [Abstract][Full Text] [Related]
14. Shared neoantigens: ideal targets for off-the-shelf cancer immunotherapy. Zhao W; Wu J; Chen S; Zhou Z Pharmacogenomics; 2020 Jun; 21(9):637-645. PubMed ID: 32423288 [TBL] [Abstract][Full Text] [Related]
15. Neoantigen: A New Breakthrough in Tumor Immunotherapy. Zhang Z; Lu M; Qin Y; Gao W; Tao L; Su W; Zhong J Front Immunol; 2021; 12():672356. PubMed ID: 33936118 [TBL] [Abstract][Full Text] [Related]
16. The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. Ward JP; Gubin MM; Schreiber RD Adv Immunol; 2016; 130():25-74. PubMed ID: 26922999 [TBL] [Abstract][Full Text] [Related]
17. Cancer Neoantigens. Schumacher TN; Scheper W; Kvistborg P Annu Rev Immunol; 2019 Apr; 37():173-200. PubMed ID: 30550719 [TBL] [Abstract][Full Text] [Related]
18. Preclinical and clinical development of neoantigen vaccines. Li L; Goedegebuure SP; Gillanders WE Ann Oncol; 2017 Dec; 28(suppl_12):xii11-xii17. PubMed ID: 29253113 [TBL] [Abstract][Full Text] [Related]
19. Neoantigens in cancer immunotherapy: focusing on alternative splicing. Huang P; Wen F; Tuerhong N; Yang Y; Li Q Front Immunol; 2024; 15():1437774. PubMed ID: 39055714 [TBL] [Abstract][Full Text] [Related]